EU follows U.S. lead in studying diabetes drugs risks
LONDON, March 26
LONDON, March 26 (Reuters) - The European Medicines Agency said on Tuesday it was investigating the possibility that two widely used classes of diabetes drugs might cause inflammation of the pancreas and pre-cancerous changes.
The decision to study so-called GLP-1 therapies and DPP-4 drugs follows similar action earlier this month by the U.S. Food and Drug Administration.
Drugs affected include Novo Nordisk's Victoza, Merck & Co's Januvia, and Onglyza from Bristol-Myers Squibb and AstraZeneca.
- U.S. Mega Millions lottery up to $400 million, 2nd-biggest ever
- Pope Francis named Time's Person of the Year |
- Uruguay becomes first country to legalize marijuana trade
- Thousands of South Africans line up to see Mandela lie in state |
- China bitcoin arbitrage ends as traders work around capital controls